@article{bfd558f2fa6d4da18ec8c4bbdf9003f6,
title = "Bevacizumab for the treatment of glioblastoma",
author = "Sajeel Chowdhary and Marc Chamberlain",
note = "Glioblastoma (GB) is the most common adult malignant primary brain tumor that arises from glial precursor cells. Survival in GB is variable ranging from 6 to 20 months notwithstanding current standard of care (SOC) treatment. Therapy has improved, but nonetheless GB is still invariably recurrent and incurable.",
year = "2013",
month = aug,
day = "1",
doi = "10.1586/14737175.2013.827414",
language = "American English",
volume = "13",
journal = "Expert Review of Neurotherapeutics",
}